IncellDx to Study Maraviroc in COVID-19 Phase 2 Clinical Trial

IncellDx will collaborate on the SARS-CoV2 Clinical Trial NCT04435522 involving Pfizer's FDA-approved CCR5 antagonist Maraviroc. The trial "Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2" seeks to establish whether a one week treatment with Maraviroc, used at its approved dosage for HIV, is safe and tolerable in patients with SARS-CoV-2.

Maraviroc, an oral medication, will be administered for seven days. Blood will be collected at Day 0, 3, 7 and 14. IncellDx is performing a Maraviroc-specific CCR5 Receptor Occupancy assay, their IncellKINE RUO Cytokine Storm quantification panel, immune profiling with T-cell exhaustion and macrophage polarization as well as SARS-CoV-2 plasma viral load (pVL) .

"Since the beginning of the COVID-19 pandemic, IncellDx has led the way in defining the role of CCR5 antagonism in diagnosis and treatment of COVID-19,” Bruce Patterson MD, CEO of IncellDx said. “We are excited to collaborate in the study of Maraviroc's potential as a therapeutic for COVID-19. In our studies, we have shown that CCR5 antagonism can restore immune homeostasis, quiet the cytokine storm, and reduce plasma viral load of SARS-CoV-2 RNA."